SURMOUNT-1
New England Journal of Medicine
72 weeks
Tirzepatide Once Weekly for the Treatment of Obesity
In SURMOUNT-1, adults without diabetes receiving once-weekly subcutaneous tirzepatide had mean body-weight changes of 15.0%, 19.5%, and 20.9% at 72 weeks at the studied 5 mg, 10 mg, and 15 mg doses.
- Studied regimen
- 5 mg, 10 mg, or 15 mg once weekly plus lifestyle intervention
Published studies have evaluated specific semaglutide and tirzepatide regimens. Those results do not establish the effectiveness of Zenbody’s compounded formulations or predict an individual patient’s results.
View published research DOI 10.1056/NEJMoa2206038

